<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671372</url>
  </required_header>
  <id_info>
    <org_study_id>APO3583g</org_study_id>
    <secondary_id>GO00933</secondary_id>
    <nct_id>NCT00671372</nct_id>
  </id_info>
  <brief_title>A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered Intravenously in Combination With Camptosar®/Erbitux® Chemotherapy or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and pharmacokinetics of adding dulanermin to
      Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus
      bevacizumab (only for Cohort 6 subjects who have not received prior bevacizumab therapy).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of dulanermin administered in combination with Camptosar and Erbitux</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab)</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohorts 1-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 6, 6A, 7, 7A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Cohorts 6, 6A, 7, 7A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)</description>
    <arm_group_label>Cohorts 6, 6A, 7, 7A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Cohorts 1-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dulanermin</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Cohorts 1-5</arm_group_label>
    <arm_group_label>Cohorts 6, 6A, 7, 7A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Cohorts 1-5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age &gt;= 18 years

          -  Histologically confirmed CRC with evidence of metastases and measurable tumor
             lesion(s)

          -  Progression of disease following, or intolerance to, treatment with
             5-fluorouracil-based therapy

          -  Progression of disease during or within =&lt; 6 months following the last dose of a prior
             first-line treatment with a fluoropyrimidine and oxaliplatin-based chemotherapy plus
             bevacizumab for metastatic disease

          -  Use of an effective means of contraception for women of childbearing potential and men
             with partners of childbearing potential (use per institutional standard)

          -  Life expectancy of &gt; 3 months

          -  Willingness and capability to be accessible for study follow-up

        Exclusion Criteria:

          -  Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure
             response

          -  Radiation therapy to a peripheral lesion within 14 days prior to Day 1; Radiation
             therapy to a thoracic, abdominal or pelvic field within 28 days prior to Day 1

          -  Chemotherapy, hormonal therapy, or immunology within 4 weeks prior to Day 1

          -  Previous exposure to DR4-targeted therapy or DR5-targeted therapy

          -  Evidence of clinically detectable ascites on Day

          -  Other invasive malignancies within 5 years prior to Day 1 (other than basal cell
             carcinoma of the skin or in situ carcinoma of the cervix)

          -  History or evidence upon physical examination of CNS disease

          -  Active infection requiring parenteral antibiotics on Day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 or anticipation of need for major surgical procedure during the course
             of the study and fine needle aspirations within 7 days prior to Day 1

          -  Pregnancy or lactation

          -  Serious nonhealing wound, ulcer, or bone fracture

          -  Current or recent participation in another experimental drug study

          -  Clinically significant cardiovascular disease

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or that might affect interpretation of
             the results of the study or render the subject at high risk from treatment
             complications

          -  Cohort 5 only: Subjects who have a Kras mutation will be excluded from enrollment

          -  The following exclusion criteria apply only to subjects who have received prior
             bevacizumab and are enrolled in Cohort 6: four or more prior doses of bevacizumab
             therapy, inadequately controlled hypertension, history of hypertensive crisis or
             hypertensive encephalopathy, history of arterial thromboembolic event 6 months prior
             to Day 1, proteinuria, history of abdominal fistula or gastrointestinal perforation
             within 6 months prior to Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia Portera, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC</keyword>
  <keyword>Metastatic CRC</keyword>
  <keyword>APO2L/TRAIL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

